135 related articles for article (PubMed ID: 12813914)
21. Herpes Simplex Virus 1 Specifically Targets Human CD1d Antigen Presentation To Enhance Its Pathogenicity.
Rao P; Wen X; Lo JH; Kim S; Li X; Chen S; Feng X; Akbari O; Yuan W
J Virol; 2018 Nov; 92(22):. PubMed ID: 30185591
[TBL] [Abstract][Full Text] [Related]
22. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
Karem KL; Bowen J; Kuklin N; Rouse BT
J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
[TBL] [Abstract][Full Text] [Related]
23. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
Bettahi I; Zhang X; Afifi RE; BenMohamed L
Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
[TBL] [Abstract][Full Text] [Related]
24. Coexpression of interleukin-2 enhances the immunization effect of a DNA vaccine expressing herpes simplex 1 glycoprotein D.
Li WR; Niu B; Wang JW; Feng ZJ; Wang DX
Acta Virol; 2006; 50(4):251-6. PubMed ID: 17177610
[TBL] [Abstract][Full Text] [Related]
25. Anti-glycoprotein g antibodies of herpes simplex virus 2 contribute to complete protection after vaccination in mice and induce antibody-dependent cellular cytotoxicity and complement-mediated cytolysis.
Görander S; Ekblad M; Bergström T; Liljeqvist JÅ
Viruses; 2014 Nov; 6(11):4358-72. PubMed ID: 25398047
[TBL] [Abstract][Full Text] [Related]
26. Protection of nude mice by passive immunization with a type-common human recombinant monoclonal antibody against HSV.
Sanna PP; De Logu A; Williamson RA; Hom YL; Straus SE; Bloom FE; Burton DR
Virology; 1996 Jan; 215(1):101-6. PubMed ID: 8553581
[TBL] [Abstract][Full Text] [Related]
27. Neuroinvasive properties of herpes simplex virus type 1 glycoprotein variants are controlled by the immune response.
Mitchell BM; Stevens JG
J Immunol; 1996 Jan; 156(1):246-55. PubMed ID: 8598469
[TBL] [Abstract][Full Text] [Related]
28. Kinetic analysis of glycoprotein C of herpes simplex virus types 1 and 2 binding to heparin, heparan sulfate, and complement component C3b.
Rux AH; Lou H; Lambris JD; Friedman HM; Eisenberg RJ; Cohen GH
Virology; 2002 Mar; 294(2):324-32. PubMed ID: 12009874
[TBL] [Abstract][Full Text] [Related]
29. Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin M antibody.
Hook LM; Lubinski JM; Jiang M; Pangburn MK; Friedman HM
J Virol; 2006 Apr; 80(8):4038-46. PubMed ID: 16571820
[TBL] [Abstract][Full Text] [Related]
30. IgG subtype is correlated with efficiency of passive protection and effector function of anti-herpes simplex virus glycoprotein D monoclonal antibodies.
Ishizaka ST; Piacente P; Silva J; Mishkin EM
J Infect Dis; 1995 Oct; 172(4):1108-11. PubMed ID: 7561190
[TBL] [Abstract][Full Text] [Related]
31. The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice.
Augustinova H; Hoeller D; Yao F
J Virol; 2004 Jun; 78(11):5756-65. PubMed ID: 15140973
[TBL] [Abstract][Full Text] [Related]
32. Induction of protective immunity with antibody to herpes simplex virus type 1 glycoprotein H (gH) and analysis of the immune response to gH expressed in recombinant vaccinia virus.
Forrester AJ; Sullivan V; Simmons A; Blacklaws BA; Smith GL; Nash AA; Minson AC
J Gen Virol; 1991 Feb; 72 ( Pt 2)():369-75. PubMed ID: 1704412
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of recombinant herpes simplex virus 1 glycoprotein D candidate vaccines in mice.
Durmanová V; Mosko T; Sapák M; Kosovský J; Rezuchová I; Buc M; Rajcáni J
Acta Microbiol Immunol Hung; 2006 Dec; 53(4):459-77. PubMed ID: 17278713
[TBL] [Abstract][Full Text] [Related]
34. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
Da Costa XJ; Morrison LA; Knipe DM
Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
[TBL] [Abstract][Full Text] [Related]
35. UL13 protein kinase of herpes simplex virus 1 complexes with glycoprotein E and mediates the phosphorylation of the viral Fc receptor: glycoproteins E and I.
Ng TI; Ogle WO; Roizman B
Virology; 1998 Feb; 241(1):37-48. PubMed ID: 9454715
[TBL] [Abstract][Full Text] [Related]
36. Dual role of B cells in mediating innate and acquired immunity to herpes simplex virus infections.
Deshpande SP; Kumaraguru U; Rouse BT
Cell Immunol; 2000 Jun; 202(2):79-87. PubMed ID: 10896767
[TBL] [Abstract][Full Text] [Related]
37. Modulation of immunity against herpes simplex virus infection via mucosal genetic transfer of plasmid DNA encoding chemokines.
Eo SK; Lee S; Chun S; Rouse BT
J Virol; 2001 Jan; 75(2):569-78. PubMed ID: 11134269
[TBL] [Abstract][Full Text] [Related]
38. Purification of herpes simplex virus glycoproteins B and C using monoclonal antibodies and their ability to protect mice against lethal challenge.
Roberts PL; Duncan BE; Raybould TJ; Watson DH
J Gen Virol; 1985 May; 66 ( Pt 5)():1073-85. PubMed ID: 2582080
[TBL] [Abstract][Full Text] [Related]
39. Protection against herpes simplex virus-induced eye disease after vaccination with seven individually expressed herpes simplex virus 1 glycoproteins.
Ghiasi H; Bahri S; Nesburn AB; Wechsler SL
Invest Ophthalmol Vis Sci; 1995 Jun; 36(7):1352-60. PubMed ID: 7775113
[TBL] [Abstract][Full Text] [Related]
40. Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies
Fukui A; Maruzuru Y; Ohno S; Nobe M; Iwata S; Takeshima K; Koyanagi N; Kato A; Kitazume S; Yamaguchi Y; Kawaguchi Y
mBio; 2023 Aug; 14(4):e0099223. PubMed ID: 37366623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
